Business context and reporting period
This is ZIOPHARM Oncology, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2021. The filing identifies the registrant as ZIOPHARM Oncology, Inc., not Alaunos Therapeutics, Inc. The company was a clinical-stage immuno-oncology developer focused primarily on its non-viral Sleeping Beauty cell-therapy platform; it had no recurring operating revenue.
Financial results and liquidity
| Metric | Q2 2021 | Q2 2020 | Six months 2021 | Six months 2020 |
|---|---|---|---|---|
| Revenue | No significant revenue from operations | No significant revenue from operations | No significant revenue from operations | No significant revenue from operations |
| Research and development expense | $13.6m | $12.1m | $26.9m | $24.8m |
| General and administrative expense | $9.1m | $6.6m | $17.3m | $12.5m |
| Net loss | $22.7m | $18.6m | $44.2m | $36.9m |
| Net loss per share | $0.11 | $0.09 | $0.21 | $0.18 |
| Operating cash used | — | — | $36.8m | $23.9m |
At June 30, cash and cash equivalents were $76.7m, down from $115.1m at December 31, 2020. Working capital was $75.8m, compared with $112.2m at year-end. The company reported $18.5m of total liabilities, comprising primarily lease liabilities and current operating accruals; it had no term loan outstanding at quarter-end. Property and equipment purchases used $2.6m of cash in the first half. There were no public-offering or ATM proceeds in that period; financing cash flow was $1.0m from option exercises.
Margins are not meaningful because the company had no significant operating revenue. Accumulated deficit was $808.3m. Management estimated that June-end cash plus $25.0m of gross loan proceeds received in August 2021 would fund planned operations into Q4 2022; this is a forward-looking estimate, not a guarantee.
Material changes versus prior comparable period
- First-half net loss increased $7.3m year over year; operating cash use increased $12.9m.
- First-half R&D expense rose $2.1m, with increased staffing, stock compensation, facilities and cell-therapy costs partly offset by lower Controlled IL-12 spending.
- First-half G&A expense rose $4.8m, primarily from employee-related costs, including expenses associated with the former CEO’s separation.
- Stock-based compensation was $7.5m in the first half versus $3.6m a year earlier. Option-life extensions for former officers and directors contributed approximately $2.0m of first-half expense.
- Unlike the first half of 2020, which included $101.7m of net financing proceeds from equity offerings and ATM sales, first-half 2021 financing proceeds were only $1.0m.
Outlook, developments and risks
- On August 6, 2021, after quarter-end, the company borrowed $25.0m under a term-loan agreement and could access another $25.0m if specified funding and clinical milestones are met. The loan bears interest at the greater of 7.75% or prime plus 4.5%, has a 5.75% final payment, and includes milestone-dependent payment and maturity extensions. A warrant to purchase 432,843 shares at $2.22 was issued at closing.
- The company expected its company-sponsored Library TCR-T Phase 1/2 treatment study to dose its first patient in the second half of 2021, subject to manufacturing readiness. It was completing process qualification at its own production unit and with its contract manufacturer.
- The Taiwan joint venture reported that two patients had received CD19 RPM CAR-T treatment with no serious adverse safety events reported. Further manufacturing-process development was required before treating additional patients; timing was unspecified and affected by COVID-related restrictions in Taiwan.
- The company announced it was winding down its existing Controlled IL-12 clinical program, while seeking a partner and exploring potential synergies with cell therapy. The NCI’s Personalized TCR-T trial had temporarily suspended enrollment for reasons described as internal to the NCI and unrelated to the company’s technology. MD Anderson closed its CD19 RPM CAR-T allogeneic Phase 1 trial and withdrew its IND in June 2021.
- Management said additional financing or partnerships would be needed after available resources are exhausted. If funding is unavailable, the company may delay or reduce development programs. The common-stock authorization and shares already issued or reserved could constrain equity financing.
- COVID-19 could disrupt trials, manufacturing, vendors and access to capital. Other significant risks include early-stage clinical evidence, manufacturing qualification and supply dependence, regulatory uncertainty, competition, licensing obligations and potential dilution or debt restrictions.
- Management concluded disclosure controls were not effective as of June 30, 2021 and identified a material weakness involving timely account reconciliation and review, attributed to insufficient accounting resources. The company said the weakness did not affect reported financial-statement amounts and remediation was in progress.
Important facts for investors to verify
- Confirm the issuer’s identity: the supplied filing is for ZIOPHARM Oncology, Inc., although the request metadata names Alaunos Therapeutics, Inc.
- Review the August 2021 loan agreement, covenants, repayment schedule and conditions for the additional $25.0m tranche.
- Assess whether the cash-runway estimate into Q4 2022 remains supportable against actual spending, clinical timelines and financing needs.
- Track Library TCR-T manufacturing qualification and first-patient dosing, plus the Taiwan CAR-T process-development timeline.
- Monitor remediation of the material weakness and whether disclosure controls become effective.
- Consider the implications of the Controlled IL-12 wind-down, the NCI trial suspension and the allogeneic CAR-T trial closure for the development portfolio.